|
Education
Eastern Washington University, BS-Nursing, Cheney, WA,1980 – 1984
University of Pennsylvania, Post Baccalaureate Pre-Med , Philadelphia, PA,1990 -1991
Medical College of Pennsylvania, Doctor of Medicine, Philadelphia, PA 1991 – 1995
Post-Graduate Education
University of Iowa Hospitals and Clinics, Iowa City, IA, Resident, Obstetrics and Gynecology, 1995-1999
University of Iowa, Iowa City, IA, K-30 Fellow, Clinical Investigation Certificate 2002 - 2004
University of Iowa Carver College of Medicine, Iowa City, IA, Master of Science - Epidemiology, 2002-2004
Certification
American Board of Obstetrics and Gynecology, recertified annually
Licensure
Iowa
Professional and Academic Positions
- Staff, Obstetrician/Gynecologist Group Health Cooperative, Olympia, WA, 1999-2002
- Associate, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA, 2002-2005
- Assistant Professor, Department of Obstetrics and Gynecology University of Iowa Hospitals and Clinics, Iowa City, IA, 2005 -2010
- Clinical Associate Professor, Department of Obstetrics and Gynecology University of Iowa Hospitals and Clinics, Iowa City, IA, 2010-
- Clinical Clerkship Director, Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA, 2010–
- Director, Vulvar Vaginal Disease Clinic
- Director, Colposcopy Clinics
Areas of Research Interest
- Lower Genital Tract Diseases
- Vulvovaginal Diseases
- Vulvodynia
Completed Projects
Federal/NIH/CDC
Primary-Investigator - K23 HD45769-01: Mentored Patient-Oriented Research Career Development Award. Vulvar Disease and Bladder and Bowel Symptoms. National Institute of Child Health and Development.
Institutional
General Clinical Research Center Pilot Grant. Vulvar Pain: Treatment trial using gabapentin.
Clinical Trials
1547-851B-62 A Randomized, USA and Canada, Multicenter, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection.
V503-001. A Randomized, International, Double-Blinded, Controlled with Gardasil, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus L1 Virus-Like Particle Vaccine administered to 16-26 year old women.
A randomized, worldwide, placebo-controlled, double-blind, study to investigate the safety, immunogenicity and efficacy on the incidence of HPV 16/18 related CIN 2/3 or worse of the Quadrivalent HPV (6,11,16,18) L1 Virus Like Particle Vaccine in 16-23 year old Women – the Future II Study.
A Phase III, double blind, randomized, controlled, multicenter study to evaluate the efficacy of HPV 16/18 VLP/ASO4 Vaccine.
A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gDAlum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.
HPV-015: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.
Co-Investigator - 1485-R851: Phase I, Rising Multiple-Dose Safety,
Pharmacokinetic, and Pharmacodynamic Study of R-851 Gel Delivered
Intravaginally to Female Subjects with Cervical Dysplasia. 3M Pharmaceuticals.
2003-2004.
Co-Investigator - A double-blind, randomized, controlled Phase III
study to assess the prophylactic efficacy and safety of gDAlum/MPL
vaccine in the prevention of genital herpes disease in young women
who are HSV-1 and -2 seronegative. National Institute of Allergy
and Infectious Diseases/GlaxoSmithKline. 2003-2004.
|